Gonzalo Recondo

@BRicciutiMD @Nature @HugoAerts @Simon_Bernatz Impressive and impactful work, congratulations!

Pleased to share our latest study in @Nature. We identify radiographic thymic health as a tumor-agnostic biomarker, hiding in plain sight, of #ICI outcomes. ⬆️thymic health associates with #ICI efficacy, ⬆️TCR diversity & TRECs. @HugoAerts @Simon_Bernatz nature.com/articles/s4158…

Esteban “Steve” Cvitkovic, MD, an emeritus member of the AACR and a medical oncologist who focused on early-stage development of cancer therapies, died June 20 at the age of 75. We offer heartfelt condolences to his family, friends, and colleagues. brnw.ch/21wYNaG

Remembering Esteban (Steve) Cvitkovic on his birthday. A deeply original scientist and mentor to many, whose clarity of thought transformed oncology—from enabling safe cisplatin use to advancing oxaliplatin and multiple therapeutic regimens. Deeply missed—but so very present

@AndresFCardonaZ Felicitaciones Andrés! Tremendo logro! Solo reflejo de la calidad profesional de tu equipo y la infraestructura del hospital! Bravo!

@BRicciutiMD @DiFedericoMD @EdoardoGarbo @valentsant @thenasheffect @ACortelliniMD @NarjustFlorezMD @DanaFarberNews @DanaFarber @IASLC Such an amazing team! Congratulations!

Closing out #WCLC25 with gratitude for physician–scientist @DiFedericoMD and our fellows @EdoardoGarbo, @valentsant, #EleonoraGariazzo I’m lucky to work with, who presented studies to help move us closer to more personalized treatments for patients with lung cancer. 👏🌍#IMG

@AndresFCardonaZ Diría el prócer argentino en educación Sarmiento: “Los discípulos son la mejor biografía del maestro”

@GlopesMd @USCIS @SylvesterCancer @ASCO Congratulations Gilberto!

I am a physician who cares for people living with cancer and looks for ways to improve how we prevent, diagnose and treat the disease. As of 8/8/25 I am also a #newUScitizen @USCIS @SylvesterCancer @ASCO Proud to officially become an American!

@StephenVLiu @Georgetown @LombardiCancer Congratulations Stephen all the best in your new role!

Honored and humbled to accept a new role as Division Chief for Hematology & Oncology at Georgetown starting next month. Excited for all that the future holds for @Georgetown @LombardiCancer with the best colleagues one could ask for.

@MariaBluthgen @barrosonco @diegomprost Igualmente querido!

@barrosonco @GRecondoMD @diegomprost Que lindo verte Max!

Qué lindo encontrar en #ASCO25 a nuestros colegas y amigos trabajando en el exterior @GRecondoMD @MariaBluthgen @diegomprost 🫂

@FernandoOnco @Amgen Mal nice to see you!!

@GRecondoMD is a big brother in #lungcancer research 🔬 Nice see you here and many thanks to help patients in Brazil 🇧🇷 with @Amgen studies

@interconsulta Grande Martín felicitaciones!

Recién salido del horno... 📰 😏 Me pone muy contento poder mostrar el trabajo que hacemos en un hospital de Argentina 🇦🇷 y que pueda ser de interés para una audiencia global nejm.org/doi/full/10.10…

@MarceloCorassa @herbloong Congrats Marcelo all the best!

This ASCO is definitely going to be different for me. A true honor to serve as a discussant and represent Brazil. I’ll be speaking on June 1st (and probably shivering) about the EGFR exon 20 insertions and HER2 mutations treatment scenario in NSCLC after the talks of @herbloong and @HelenaYu923! Excited! #ASCO25

@ogarrieta @NatureComms @incanMX Congratulations Oscar!

We reported in @NatureComms, this phase 2 trial, the combination of alectinib and bevacizumab (ALEK-B) in patients with advanced ALK rearranged NSCLC from @incanMX, the 12-month PFS rate was 97.1% The 36-month PFS and OS rates were 64.2% and 87.9% respectively. The ORR was 100%, and the 36-month icPFS rate was 87.8%. Grade 3–4 adverse events occurred in 46.3% of patients, most commonly proteinuria and hepatotoxicity, QoL significantly improved from baseline at 12 months and was maintained through 36 months. These findings support the efficacy and safety of alectinib plus bevacizumab and justify further investigation in ALK-rearranged NSCLC. nature.com/articles/s4146… @AndresFCardonaZ @Ecaballep @LuisLara_M @JordiRemon

@ChristianRolfo @UBAonline @OhioStateMedOnc @rolfolab Congratulations Christian! Gran reconocimiento!

Very honored of this important recognition in my born country. Blessed to share this special moment with my family, friends and great colleagues from Argentina 🇦🇷 looking forward to continue working with @UBAonline from OSU @OhioStateMedOnc ! Thanks to all my team @rolfolab

@RobertoFerrara_ @MyUniSR @AntonioNuccio01 @FabioSalomone22 @LudovicaMollica Bravo Roberto!

Exchanging projects and ideas on neoadjuvant versus perioperative chemio -IO, quality of life in early stage NSCLC, acquired resistance to ICI in metastatic NSCLC. Proud and lucky to work with these people. @MyUniSR #ELCC2025 @AntonioNuccio01 @FabioSalomone22 @LudovicaMollica

@gastonzco @BadalonaTres60 Grande Gastón

Cada acción cuenta, Gracias a @BadalonaTres60 por su compromiso en la lucha contra el cáncer . 🩻 Detección precoz 🚴‍♀️ Hábitos saludables 🧬 Tratamientos oncológicos específicos Son Pilares clave para seguir mejorando la supervivencia.

@geoff_oxnard Congrats Geoff! All the best I your new role!

Excited to announce I'm joining BlossomHill Therapeutics as CMO! I’ve always believed in patient-centered cancer therapies. None better to team with than our CEO Jean Cui who designed some of the most effective & creative macrocyclic TKIs on the market: businesswire.com/news/home/2025…

@cbaldotto Congratulations Clarissa! All the best in your new role!

It is such a great honor to be elected as President of the Brazilian Society of Medical Oncology for 2026! A lot of work ahead.

We’re honored! 🏆 Amgen’s trailblazing innovation in small cell lung cancer (#SCLC) was named one of @TIME’s Best Inventions of 2024. #TimeBestInventions

Important piece on supporting our international medical graduates (IMGs) in hematology/oncology. The IMGs I've had the pleasure of working with over the years have been among the best mentors, mentees, teachers, physicians, and researchers. ascopubs.org/doi/10.1200/OP…